Incyte is developing a first-in-class, selective arginase inhibitor.*

Arginase is an enzyme produced by immunosuppressive myeloid cells that prevents activation of effector T cells and NK cells in tumors. Arginase exerts its immunosuppressive effect by depleting the amino acid arginine in the TiME, which subsequently prevents activation and proliferation of cytotoxic T cells and NK cells. Inhibition of arginase activity reverses this immunosuppressive block and helps restore T-cell function. In preclinical models, arginase inhibition has been shown to enhance antitumor immunity and inhibit tumor growth.

*In collaboration with Calithera BioSciences, Inc.


image show jak target.image of pi3kδ target.image of fgfr target.image of brd target.image of pim target molecule.image of lsd1 target molecule.image shows ido1 target.image shows arg target.image of pd-1 target molecule. image of gitr target molecule. image of ox40 target molecule.  image of Tim-3 target moleculeimage of Lag-3 target moleculeimage of Axr target molecule